Tech Transfer Summit set to be held next week in Adelaide

Following on from a successful first-ever Tech Transfer Summit (TTS) Australia in 2013, the TTS Global Initiative and AusBiotech are pleased to confirm the Australian chapter will be returning to South Australia next week with the support of major partner BioSA.

Alchemia, Mesoblast hire new CFOs

Former Mesoblast (ASX:MSB) CFO Jenni Pilcher has joined Alchemia (ASX:ACL), while former Novartis ANZ CFO 

Paul Hodgkinson will fill the vacant position at Mesoblast.

Orthocell aces tennis elbow trial

Orthocell's (ASX:OCC) autologous cell therapy Ortho-ATI improved grip strength in chronic tennis elbow patients by an average of 207% at 4.5 years post-treatment.

Consultation begins for new Industry Skills Fund

The federal government's new $476 million Industry Skills Fund is due to commence 1 January 2015 and a consultation has commenced in preparation, which includes webinars, a discussion paper and a digital questionnaire.

Bionomics posts maiden profit for FY14

Income from Bionomics' (ASX:BNO) licensing deal with Merck for Alzheimer's candidate BNC375 helped the company report its first post-tax operating profit for the last financial year.

Starpharma loss widens during "important" year

Starpharma put a chunk of its free cash to good use during FY14, making progress with its drug delivery, antimicrobial and agribusiness programs.

ResMed launches new sleep breathing devices, platform

ResMed (SSX:RMD) has unveiled its new Air Solutions sleep-disordered breathing therapy platform, including the flagship AirSense 10 positive airway pressure devices.

NHMRC reports on progress to improve clinical trials

The National Health and Medical Research Council (NHMRC), tasked with implementing a range of initiatives designed to make the process of initiating and conducting clinical trials in Australia significantly more efficient and cost effective, has reported on the progress of work under the initiative and advised it will update the information monthly.

Lead site for Innate's SPMS trial wins ethics nod

Innate Immunotherapeutics (ASX:IIL) announced that WANRI - lead site for its phase IIb trial of MIS416 in secondary progressive multiple sclerosis - has been cleared to start recruiting patients.

QRxPharma abandons MoxDuo development

QRxPharma (ASX:QRX) has ceased development of dual-opioid drug MoxDuo, after the board decided that the cost of additional trials sure to be required for US approval could not be justified.

Industry leaders propose AIM Incentive to boost innovation

Australian industry leaders have proposed an Australian Innovation & Manufacturing (AIM) Incentive in submissions to the Senate's inquiry into Australia's innovation system.

Perth's Orthocell lists on ASX

Orthocell (ASX:OCC) has listed on the ASX following last month's $8m IPO and started receiving royalty revenue from China for regenerative medicine product Ortho-ACI.

CSL's FY14 profit grows 8% to $1.4bn

CSL (ASX:CSL) has reported an 8% growth in FY14 profit, despite the impact of a legal settlement and a decline in sales at its bioCSL division.

Bespoke biotech

Additive manufacturing and 3D printing technology have a lot to offer makers of biomedical devices.

International bio-industry associations join to comment on the USPTO's subject matter eligibility guidance

Biotech industry associations join forces to express concerns about changes to US non-statutory patent law.